

US Appl. No. 09/936499
Docket No. MWH-0031US

REMARKS

This paper is being submitted in response to the Office Action dated September 9, 2003 (PTO Paper No. 0803), wherein the examiner (1) objects to the specification insofar as it contains an error with respect to the date the priority application was filed; (2) rejects claim 5 under 35 U.S.C. § 112, second paragraph; and (3) rejects claims 1 and 5 as being unpatentable under 35 U.S.C. § 103(a).

With regard to item (1), Applicant has amended the specification such that the specification now contains an accurate statement with respect to priority. No new matter has been added to the application as a result of this amendment.

With regard to item (2), Applicant has amended claim 5 such that the claim now satisfies the requirements of 35 U.S.C. § 112, second paragraph. No new matter has been added to the application as a result of this amendment.

With regard to item (3), without acceding to the rejection, Applicant has amended claim 1 by incorporating into the claim the limitations of claim 2, which is herein canceled. Since the examiner has indicated that previously presented claims 2-4 are allowable, this amendment, combined with the re-numbering of claims 3-5 as claims 2-4, respectively, should place the application in condition for allowance.

Respectfully submitted,



Matthew M. Catlett
Registration No. 44,067
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
203.776.1450
203.492.4474 (fax)